Samsung Biologics

207940.KO

549.53 USD

21.19

+4.01%

Overview

Last close

549.53 usd

Market cap

39.11B usd

52 week high

662.75 usd

52 week low

499.98 usd

Target price

724.02 usd

Valuation

P/E

N/A

Forward P/E

65.3595

Price/Sales

15.2189

Price/Book Value

5.7197

Enterprise Value

37.21B usd

EV/Revenue

15.1791

EV/EBITDA

33.157

Key financials

Revenue TTM

2.84B usd

Gross Profit TTM

1.06B usd

EBITDA TTM

1.21B usd

Earnings per Share

N/A usd

Dividend

N/A usd

Total assets

12.27B usd

Net debt

N/A usd

About

Samsung Biologics Co.,Ltd. engages in the contract development and manufacturing organization (CDMO) business for biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates in two segments, CDMO, and Biopharmaceutical Development and Commercialization. Its development services include discovery, cell line development, process development, and clinical manufacturing. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the research and commercialization of biosimilar drugs; development and manufacture of antibody-drug conjugates; and manufactures mammalian and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.